Haraldsdóttir KH, Ingvar C, Stenram U, Tranberg KG. Long-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer. Anticancer Res. 2015 Nov; 35(11): 6147-52.
Haraldsdottir KH, Ivarsson K, Jansner K, Stenram U, Tranberg K-G. Changes in immunocompetent cells after interstitial laser thermotherapy of breast cancer. Cancer Immunol Immunother 2011; 60: 847-56
Huld Haraldsdottir K, Ivarsson K, Götberg S, Ingvar C, Stenram U, Tranberg K-G. Interstitial laser thermotherapy (ILT) for breast cancer: initial experience. Eur J Surg Oncol 2008; 34: 739-745
Tranberg K-G. Laser tumor thermotherapy: Is there a clinically relevant effect on the immune system? Biophotonics and Immune Responses, Biomedical Optics, Proceedings of SPIE, 2006; 6087: 60870, B-1–B-12 (invited paper)
Tranberg K-G, Ivarsson K, Willner J, Håkansson L, Stenram U. Induction of a distant anti-tumour effect by interstitial laser thermotherapy (ILT) in a patient with malignant melanoma. 2nd International Conference on Tumor Microenvironment: Progression, Therapy and Prevention, Baden, Austria 2002, p 49
Tranberg K-G, Möller PH, Hannesson P, Stenram U. Interstitial laser treatment of malignant tumours: initial experience. Eur J Surg Oncol 1996; 22: 47-54
Tranberg K-G, Möller PH. Interstitial laser thermotherapy: preliminary experience in patients. SPIE 1995; PM 25: 468-476
There are currently no clinical studies with MRI-guided laser ablation with the TRANBERG® | Cancer Immunotherapy System.
All publications in this page refers to treatment with CLS method imILT® which aims at achieving an immunologic response. Treatment was conducted with less advanced and developed products compared to the TRANBERG® | Cancer Immunotherapy System. The system has not yet a market clearance for Immune stimulating interstitial laser thermotherapy - imILT® by the Food and Drug Administration (FDA) in the United States of America (USA).